Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molnupiravir, an Oral Antiviral Treatment for COVID-19
William A. Fischer, Joseph J. Eron, Wayne Holman, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 209

Showing 1-25 of 209 citing articles:

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
Angélica Jayk Bernal, Monica Maria Gomes da Silva, Dany Badibanga Musungaie, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 6, pp. 509-520
Open Access | Times Cited: 1638
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
Wen Wen, Chen Chen, Jiake Tang, et al.
Annals of Medicine (2022) Vol. 54, Iss. 1, pp. 516-523
Open Access | Times Cited: 394
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100794-100794
Open Access | Times Cited: 262
Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs
Louis D. Saravolatz, Shawn Depcinski, Mamta Sharma
Clinical Infectious Diseases (2022) Vol. 76, Iss. 1, pp. 165-171
Open Access | Times Cited: 258
Molnupiravir in COVID-19: A systematic review of literature
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2021) Vol. 15, Iss. 6, pp. 102329-102329
Open Access | Times Cited: 212
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
Mohd Imran, Mandeep Kumar Arora, Syed Mohammed Basheeruddin Asdaq, et al.
Molecules (2021) Vol. 26, Iss. 19, pp. 5795-5795
Open Access | Times Cited: 163
Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir
Ravi Shankar Prasad Singh, Sima S. Toussi, Frances Hackman, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 112, Iss. 1, pp. 101-111
Open Access | Times Cited: 137
Potential therapeutic options for COVID-19: an update on current evidence
Zahra Niknam, Ameneh Jafari, Ali Golchin, et al.
European journal of medical research (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 136
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19
José Ramón Arribas, Sanjay Bhagani, Suzana M. Lobo, et al.
NEJM Evidence (2021) Vol. 1, Iss. 2
Closed Access | Times Cited: 104
Molnupiravir and Its Antiviral Activity Against COVID-19
Lili Tian, Zehan Pang, Maochen Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 102
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
Alexandra Schäfer, David R. Martinez, John J. Won, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 643
Open Access | Times Cited: 67
COVID-19 and liver disease
Jean‐François Dufour, Thomas Marjot, Chiara Becchetti, et al.
Gut (2022) Vol. 71, Iss. 11, pp. 2350-2362
Closed Access | Times Cited: 67
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
Ju Hwan Jeong, Santosh Chokkakula, Seong Cheol Min, et al.
Antiviral Research (2022) Vol. 208, pp. 105430-105430
Open Access | Times Cited: 67
Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
Ching‐Chi Lee, Chih‐Chia Hsieh, Wen‐Chien Ko
Antibiotics (2021) Vol. 10, Iss. 11, pp. 1294-1294
Open Access | Times Cited: 76
RdRp inhibitors and COVID-19: Is molnupiravir a good option?
Seyed Mohammad Reza Hashemian, Mohammad Hossein Pourhanifeh, Michael R. Hamblin, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112517-112517
Open Access | Times Cited: 70
Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic
Peter J. Hotez, Carolina Batista, Yanis Ben Amor, et al.
EClinicalMedicine (2021) Vol. 39, pp. 101053-101053
Open Access | Times Cited: 66
Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants
Jialing Yin, Chengcheng Li, Chunhong Ye, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 824-837
Open Access | Times Cited: 64
Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates
Liliana Rodrigues, Renata Bento Cunha, Tatiana Vassilevskaia, et al.
Molecules (2022) Vol. 27, Iss. 9, pp. 2723-2723
Open Access | Times Cited: 63
Pharmacological treatment of COVID-19: an opinion paper
Alberto García‐Lledó, Javier Gómez‐Pavón, Juan González del Castillo, et al.
Revista Española de Quimioterapia (2021) Vol. 35, Iss. 2, pp. 115-130
Open Access | Times Cited: 62
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
Judith M. White, Joshua T. Schiffer, Rachel Bender Ignacio, et al.
mBio (2021) Vol. 12, Iss. 6
Open Access | Times Cited: 57
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era
Huahao Fan, Fuxing Lou, Junfen Fan, et al.
The Lancet Microbe (2021) Vol. 3, Iss. 2, pp. e91-e91
Open Access | Times Cited: 56
Recent review of COVID-19 management: diagnosis, treatment and vaccination
Vivek P. Chavda, Suneetha Vuppu, Toshika Mishra, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1120-1148
Open Access | Times Cited: 55
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge
Ben Killingley, Alex Mann, Mariya Kalinova, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 51
Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
Rui Li, Hanting Liu, Christopher K. Fairley, et al.
International Journal of Infectious Diseases (2022) Vol. 119, pp. 87-94
Open Access | Times Cited: 51
Page 1 - Next Page

Scroll to top